Bovine Ephemeral Fever Virus

Overview and Taxonomy of Bovine Ephemeral Fever Virus

Taxonomic Position and Virion Architecture

Bovine ephemeral fever virus (BEFV) is the archetypal and most economically significant member of the genus Ephemerovirus within the family Rhabdoviridae, order Mononegavirales [3, 24, 29]. This taxonomic placement is grounded in the virus’s characteristic bullet-shaped or cone-shaped morphology, a hallmark of rhabdoviruses, and its negative-sense, single-stranded RNA genome, which is approximately 14.8–15.0 kilobases in length [14, 15, 27]. The BEFV virion is enveloped, with a helical nucleocapsid core, and its surface is studded with transmembrane glycoprotein (G) spikes that are critical for host cell attachment, fusion, and the elicitation of neutralizing antibodies [20, 26]. The genome organization of BEFV is complex relative to other rhabdoviruses, following the canonical order 3′-N-P-M-G-GNS-α1-α2-β-γ-L-5′, which includes at least six structural proteins (nucleoprotein N, phosphoprotein P, matrix protein M, glycoprotein G, and the large RNA-dependent RNA polymerase L) and several accessory or non-structural proteins (GNS, α1, α2, β, γ) [15, 27]. The G protein, a class I transmembrane protein, is the primary target for virus neutralization and harbors at least four distinct neutralizing epitopes (designated G1, G2, G3, and G4), with the G1 epitope being particularly immunodominant and critical for protective immunity [12, 20, 25]. The presence of an additional glycoprotein gene, GNS, which is unique to ephemeroviruses, distinguishes BEFV from the more widely studied vesiculoviruses and lyssaviruses within the Rhabdoviridae family [16, 27].

Phylogenetic Classification and Global Lineages

Phylogenetic analyses, primarily based on the complete or partial sequences of the glycoprotein (G) gene and the L gene, have consistently delineated BEFV isolates into four major global lineages: the East Asian lineage, the Middle Eastern lineage, the Australian lineage, and the African lineage [2, 9, 23, 28]. This classification reflects both the geographic origin of the isolates and their evolutionary divergence, which is driven by the virus’s high mutation rate as an RNA virus and the episodic nature of its transmission by arthropod vectors. The East Asian lineage is the most genetically diverse and has been further subdivided into at least four distinct sublineages, with recent isolates from Southwest China (e.g., BEFV/CQ1/2022) forming a novel sublineage 2, distinct from earlier Chinese and Taiwanese strains [9, 23]. Crucially, for the first time, recombination events have been identified among East Asian BEFV isolates, particularly within the G and P genes, suggesting that genetic reassortment and recombination contribute to the emergence of novel viral variants [9, 10].

The Middle Eastern lineage comprises isolates from Iran, Turkey, Israel, India, and Egypt, which share a high degree of nucleotide identity (97–99%) within the lineage [2, 14, 18, 28]. Notably, BEFVs circulating in Iran during the 2012–2013 outbreaks were initially classified as East Asian lineage but were subsequently replaced by the Middle Eastern lineage, which has become dominant in the region [2]. A large epizootic in 2020 across Turkey and Iran was caused by a genetically homogeneous cluster within this lineage, with no significant amino acid substitutions in the G protein compared to earlier Middle Eastern strains, implying that host, environmental, or vector-related factors, rather than antigenic drift, drove the outbreak’s magnitude [2, 7]. However, a novel amino acid substitution, H51Y, within the G3 epitope was identified in a 2022 isolate from Kermanshah, Iran, signaling ongoing intra-lineage evolution and potential antigenic diversification [2]. The African lineage is represented by isolates from South Africa and other sub-Saharan African countries, and the Australian lineage includes strains from mainland Australia and the Australian vaccine strain 919, which is widely used commercially [5, 15, 23]. The vaccine strain (Ultravac®) is a live attenuated derivative of the Australian 919 isolate, and its genome sequence, as well as that of a South African field strain, have been fully characterized [15, 21].

Serotype Uniformity and the Conceptualization of Novel Ephemeroviruses

Despite the considerable genetic heterogeneity observed between lineages, BEFV is considered to exist as a single serotype globally [27]. Extensive cross-neutralization studies have indicated that polyclonal antisera raised against isolates from one lineage are capable of neutralizing isolates from other lineages, suggesting that the major neutralizing epitopes, particularly the G1 epitope, are highly conserved [1, 12, 25]. This antigenic stability has practical implications for vaccine development, as a vaccine based on one lineage (e.g., the Australian 919 strain) is expected to confer protection against heterologous strains, albeit with potentially variable effectiveness [5, 8, 11]. However, the discovery of novel ephemeroviruses, such as Hayes Yard virus (HYV) and Puchong virus (PUCV), which are closely related to BEFV but antigenically distinct, underscores the diversity within the genus Ephemerovirus [27]. HYV was isolated from a bull in Australia exhibiting severe neurological signs indistinguishable from BEF, and its complete genome shares the same complex organization as BEFV but clusters independently in phylogenetic analyses based on the L protein, suggesting it represents a distinct viral species within the genus [27]. This finding highlights that the clinical syndrome known as bovine ephemeral fever may be caused by a broader range of ephemeroviruses than previously recognized.

Host Range, Geographic Distribution, and Economic Significance

BEFV has a defined host range, primarily affecting domestic cattle (Bos taurus and Bos indicus) and water buffalo (Bubalus bubalis), in which it causes an acute, debilitating febrile illness [24, 29, 31]. Serological surveys have demonstrated exposure in a variety of wild and domestic ruminants, including cervids (deer), sheep, goats, and feral water buffalo, but these species are generally considered incidental or spillover hosts rather than true reservoirs, as they rarely exhibit clinical disease and neutralizing antibody prevalence is often low and temporally linked to outbreaks in cattle [6, 13, 17, 31]. For instance, a longitudinal study in Israel found that fewer than 1% of wildlife samples (including mountain gazelles and Mesopotamian fallow deer) had BEFV-neutralizing antibodies, with all seropositives collected from regions that had experienced recent bovine outbreaks, suggesting these populations do not maintain independent transmission cycles [31]. In contrast, cervids in the Republic of Korea showed a higher seroprevalence (10.8%), with older age and proximity to ruminant farms as significant risk factors, indicating that deer may play a more substantial role in local epidemiology, possibly as amplifying hosts or sentinels [13].

Geographically, BEFV is enzootic across tropical, subtropical, and warm temperate regions of Africa, Asia (including the Middle East, South Asia, Southeast Asia, and East Asia), and Australia [3, 24, 29]. The virus is responsible for seasonal epizootics that coincide with the peak activity of its arthropod vectors, typically occurring during summer, autumn, and monsoon periods [4, 19, 24]. The disease is classified as a WOAH (World Organisation for Animal Health)-listed disease due to its significant impact on international trade in livestock and animal products, and its potential for transboundary spread via infected vectors or animal movement is a growing concern, particularly for naive regions such as Europe and the Americas [3, 30]. The economic losses attributable to BEFV are substantial, driven by a sudden and drastic reduction in milk yield (often exceeding 80% in affected lactating cows), weight loss in beef cattle, abortion, temporary infertility in bulls, and mortality rates that can reach 1–5% in severe outbreaks [24, 30]. A national-scale study in Israel used herd-level data to calculate that the cumulative economic impact per outbreak, including the cost of lost milk production and premature culling of valuable cows, was considerable, with effects persisting for months after clinical recovery [30]. The risk of BEFV emergence in Europe is increasingly acknowledged, especially in light of climate change-facilitated expansion of Culicoides vector populations and the precedent set by the incursions of bluetongue virus and Schmallenberg virus into previously naive European territories [3, 30]. As a vector-borne pathogen with high morbidity and no specific antiviral therapeutics, BEFV remains a critical target for coordinated surveillance, rapid diagnostic capacity, and strategic vaccination programs in endemic and at-risk regions [1, 22, 24].

Molecular Pathogenesis of Bovine Ephemeral Fever Virus

The molecular pathogenesis of bovine ephemeral fever virus (BEFV) represents a sophisticated and multi-layered interplay between viral replication strategies and host cellular machinery. As the type species of the genus Ephemerovirus within the family Rhabdoviridae, BEFV exhibits a complex negative-sense, single-stranded RNA genome of approximately 14.9 kilobases that encodes five structural proteins (N, P, M, G, and L) and several accessory proteins (α1, α2, α3, β, and γ) with critical roles in modulating the host cellular environment [14, 15, 21, 23]. The pathogenesis of BEFV is characterized by an acute, transient, and febrile illness that, despite its short duration (typically 3–5 days), induces profound physiological derangements, including severe leukopenia, hypocalcemia, and systemic inflammatory responses [24, 34, 39, 41]. The molecular underpinnings of these clinical manifestations are rooted in the virus’s ability to hijack host signaling pathways, subvert innate immune defenses, and manipulate fundamental cellular processes such as endocytosis, autophagy, and apoptosis.

Viral Entry: Orchestrated Signaling Cascades and Clathrin-Mediated Endocytosis

The entry of BEFV into susceptible host cells is not a passive event but rather an exquisitely regulated process requiring the coordinated activation of multiple host signaling cascades. The viral glycoprotein G, a class I transmembrane protein responsible for receptor attachment and membrane fusion, engages host cell surface receptors to initiate entry [12, 26]. Crucially, BEFV entry follows a clathrin-mediated and dynamin 2-dependent endocytosis pathway that is actively promoted by the virus through the stimulation of specific signaling networks [43]. Upon virus binding, BEFV simultaneously activates the Src-JNK-AP1 and PI3K-Akt-NF-κB signaling pathways, a dual activation strategy that distinguishes BEFV from other rhabdoviruses such as vesicular stomatitis virus (VSV), which activates only the Src-JNK pathway [43]. This concurrent activation is essential because it drives the transcriptional upregulation of clathrin and dynamin 2, the core machinery required for efficient virus internalization.

The signaling cascade is further amplified through a positive feedback loop involving cyclooxygenase-2 (Cox-2). BEFV infection triggers the synthesis of prostaglandin E2 (PGE2) via Cox-2 activation, and PGE2 subsequently signals through G-protein-coupled E-prostanoid (EP) receptors EP2 and EP4 in an autocrine or paracrine manner [43]. This PGE2/EP receptor signaling enhances the downstream activation of both Src-JNK-AP1, via a cAMP-dependent mechanism, and PI3K-Akt-NF-κB, via a cAMP-independent mechanism, thereby boosting clathrin and dynamin 2 expression to facilitate viral entry [43]. The importance of this pathway is underscored by the observation that pharmacological inhibition of adenylate cyclase, which produces cAMP, significantly reduces Src phosphorylation and the expression of endocytic machinery components, consequently impairing BEFV entry. This multi-pronged signaling strategy ensures that BEFV can efficiently invade host cells while simultaneously preparing the cellular environment for subsequent replication steps.

Subversion of Innate Immunity: A Multi-Pronged Offensive Against the Type I Interferon System

Once inside the host cell, BEFV faces a formidable antiviral defense: the type I interferon (IFN) signaling pathway. The mitochondrial antiviral signaling protein (MAVS) serves as a central adaptor molecule that relays signals from cytosolic RNA sensors, such as RIG-I and MDA5, to downstream transcription factors, including IRF3 and IRF7, ultimately leading to the production of type I IFNs and the establishment of an antiviral state. BEFV has evolved a remarkably sophisticated arsenal of mechanisms to dismantle this critical host defense.

One of the most significant discoveries in BEFV pathogenesis is the virus’s ability to co-opt host proteins to promote the proteasomal degradation of MAVS. The receptor for activated C kinase 1 (RACK1) is upregulated upon BEFV infection and acts as a potent negative regulator of MAVS signaling [35]. RACK1 achieves this by upregulating the expression of STIP1 homology and U-box containing protein 1 (STUB1), an E3 ubiquitin ligase. STUB1 then catalyzes the ubiquitination of MAVS, targeting it for degradation via the ubiquitin-proteasome system [35]. This degradation effectively abrogates IFN signaling, allowing BEFV to replicate unchecked. The functional significance of this axis is demonstrated by the fact that RACK1 knockdown significantly inhibits BEFV replication, while its overexpression promotes viral growth [35].

Similarly, the mitochondrial single-stranded DNA-binding protein 1 (SSBP1), a component of the mitochondrial DNA replisome, is upregulated during BEFV infection and acts as a critical negative regulator of MAVS-mediated immune responses [33]. SSBP1 induces K48-linked ubiquitination of MAVS, but interestingly, this ubiquitination is catalyzed by a different E3 ubiquitin ligase, Smad ubiquitin regulatory factor 1 (Smurf1), not STUB1 [33]. This suggests that BEFV employs multiple, non-redundant pathways to ensure MAVS degradation. The identification of A01, a specific Smurf1 inhibitor, as a compound that blocks SSBP1-induced MAVS degradation and enhances antiviral signaling, highlights a potential therapeutic target against BEFV [33].

Beyond the direct targeting of MAVS, BEFV manipulates the interferon regulatory factor (IRF) family to further dampen IFN signaling. Interferon regulatory factor 8 (IRF8) is upregulated upon BEFV infection and, paradoxically, promotes viral replication [32]. Mechanistically, IRF8 suppresses the type I IFN signaling pathway by promoting the degradation of IRF9, a critical component of the ISGF3 transcription factor complex that drives the expression of interferon-stimulated genes (ISGs). IRF8 achieves this by upregulating the expression of NEDD4 Like E3 ubiquitin ligase (NEDD4L), which then targets IRF9 for ubiquitin-proteasome degradation [32]. This IRF8-NEDD4L-IRF9 axis represents a novel mechanism by which BEFV hijacks the host cell’s own transcriptional regulatory machinery to disarm the IFN response.

The virus also exploits the host microRNA machinery to suppress MAVS expression. BEFV infection significantly upregulates the expression of miR-3470b, a microRNA that directly targets the 3’ untranslated region of MAVS mRNA, thereby reducing MAVS protein levels [40]. Transfection with a miR-3470b mimic enhances BEFV replication, while inhibition of miR-3470b has the opposite effect, confirming the functional relevance of this post-transcriptional regulatory mechanism [40]. This convergence of multiple degradation and silencing strategies upon a single host protein, MAVS, underscores the central importance of this antiviral hub in the host defense against BEFV and the virus’s evolutionary imperative to neutralize it.

Manipulation of Host Cell Fate: Apoptosis and Autophagy as Double-Edged Swords

BEFV exerts profound control over host cell fate decisions, specifically apoptosis and autophagy, and repurposes these processes to favor viral replication. Infection with BEFV robustly induces apoptosis, a programmed cell death pathway that, in many viral infections, serves as a host defense mechanism to limit viral spread. However, BEFV has co-opted this process to its advantage. The viral non-structural protein α3 is a key inducer of apoptosis; its overexpression activates caspase 3, leading to the cleavage of poly (ADP-ribose) polymerase (PARP) and the execution of the apoptotic program [36]. Critically, pharmacological inhibition of caspases using Z-VAD-FMK reduces BEFV titers, while treatment with the apoptosis inducer CCCP enhances virus replication, indicating that apoptosis is beneficial, not detrimental, to BEFV [36].

The molecular interplay between BEFV and the host protein heterogeneous nuclear ribonucleoprotein K (hnRNP K) is central to the regulation of virus-induced apoptosis. HnRNP K acts as a host restriction factor; its overexpression suppresses BEFV replication, while its knockdown promotes it [36]. HnRNP K exerts its antiviral effect by binding to and promoting the degradation of the viral α3 transcript, thereby inhibiting α3-induced apoptosis. However, BEFV retaliates by activating caspase 3, which cleaves and degrades hnRNP K, effectively removing this cellular brake on viral replication [36]. This elegant molecular arms race, where the virus degrades a host protein that degrades a viral transcript, highlights the dynamic and intricate nature of virus-host interactions.

In parallel with apoptosis, BEFV is a potent inducer of autophagy, a lysosomal degradation pathway that typically recycles cellular components in response to stress. BEFV triggers a complete autophagic response, characterized by the formation of autophagosomes and their fusion with lysosomes to form autolysosomes [38]. The virus activates autophagy through two distinct signaling arms: upregulation of the PI3K/Akt/NF-κB and Src/JNK/AP1 pathways in the early to middle stages of infection, and suppression of the PI3K/Akt/mTOR pathway at the late stage, with mTOR inhibition being a classic trigger for autophagy induction [38, 42]. Mechanistically, BEFV disrupts the inhibitory interaction between Beclin 1 and Bcl-2 via JNK-mediated phosphorylation of Bcl-2, thereby freeing Beclin 1 to initiate autophagosome formation [38]. The viral M protein has been identified as a key viral factor responsible for inducing autophagy through suppression of the PI3K/Akt/mTORC1 pathway [38].

The functional significance of autophagy for BEFV is unequivocal: pharmacological inhibition of autophagy with 3-methyladenine (3-MA) or knockdown of autophagy-related genes (e.g., ATG5, ATG7) with shRNAs significantly reduces BEFV replication, indicating that BEFV-induced autophagy is proviral [38, 42]. Furthermore, disrupting autophagosome-lysosome fusion by depleting LAMP2 also reduces virus yield, demonstrating that the complete autophagic flux, including autolysosome formation, is required for optimal virus production [38]. The anti-inflammatory drugs aspirin and 5-aminoimidazole-4-carboxamide riboside (AICAR) have been shown to inhibit BEFV replication by suppressing BEFV-induced autophagy, providing a mechanistic link between existing therapeutics and potential antiviral strategies [42].

Viral Assembly and Egress: Annexin A2 and Matrix Protein Interactions

The final stages of the BEFV life cycle, assembly and budding, are also subject to intricate host factor regulation. The viral matrix (M) protein plays a central role in orchestrating virus assembly and promoting the release of mature virions. However, the M protein requires assistance from host proteins to efficiently target the plasma membrane for budding. Annexin A2 (AnxA2), a calcium- and lipid-binding protein involved in vesicular trafficking and membrane organization, is upregulated upon BEFV infection [37]. AnxA2 directly interacts with the BEFV M protein, and this interaction is critical for mediating the localization of the M protein to the plasma membrane, the site of virus budding [37]. The C-terminal domain (amino acids 268–334) of AnxA2 is essential for this interaction.

Functional studies confirm the importance of this partnership: overexpression of AnxA2 promotes the release of mature virus particles, while siRNA-mediated knockdown of AnxA2 significantly inhibits BEFV replication [37]. Notably, the deletion of the AnxA2-V domain attenuates the virus-promoting effect of AnxA2, further validating the specificity of this interaction. This mechanism reveals that BEFV not only manipulates early and middle stages of infection (entry, immune evasion, autophagy) but also commandeers host proteins in the final stages of its life cycle to ensure efficient dissemination. Collectively, these molecular mechanisms, ranging from the orchestrated signaling cascades required for entry to the multi-pronged assault on MAVS, the hijacking of apoptosis and autophagy, and the recruitment of annexin A2 for egress, paint a comprehensive picture of BEFV as a master manipulator of the host cell, whose molecular pathogenesis is defined by its ability to turn the host’s own cellular processes against itself.

Clinical Manifestations and Pathological Findings in Cattle

Bovine ephemeral fever (BEF) presents a remarkably acute, biphasic, and transient clinical syndrome in cattle, a course so stereotypical that the disease is colloquially known as “three-day sickness” or “three-day stiff-sickness.” However, the seemingly benign moniker belies a profoundly debilitating illness with significant pathophysiological complexity, a high morbidity rate often reaching 80–100%, and a case fatality rate that, while typically low (reported as 12.25% in some endemic settings), can surge dramatically in high-value dairy and beef herds [4, 24]. The clinical picture is not a simple febrile event; it is the visible culmination of a sophisticated viral orchestration of host cellular machinery, involving profound calcium dysregulation, a systemic acute phase response, and complex vascular and musculoskeletal pathology. In cattle, the incubation period following natural vector-borne transmission is short, generally ranging from 2 to 10 days, with the sudden onset of clinical signs marking the peak of viremia [24, 45].

The Febrile Phase and Systemic Manifestations

The hallmark of BEF is a sudden, dramatic biphasic fever, with rectal temperatures soaring to 40–42°C (104–108°F) [19, 24]. This is not a gradual ascent; affected cattle are often found in a state of acute distress, with a dry muzzle, severe congested mucous membranes, foamy salivation, and a staring, anxious expression [19]. The initial fever spike triggers a cascade of systemic signs: pronounced dullness, depression, anorexia, and a cessation of rumination. The animal exhibits generalized shivering and muscle tremors, which can progress to a rapid, shallow respiration (tachypnea) [19, 39]. This respiratory component is a critical clinical finding; while not always present, it signals the potential for pulmonary complications. The profound pyrexia is accompanied by a significant shift in the hemogram. Neutrophil counts are markedly elevated (neutrophilia), while lymphocyte counts show a statistically significant decrease (lymphopenia), a pattern consistent with a strong systemic inflammatory response and stress leukogram [39]. Concomitantly, there is a severe and clinically important hypocalcemia. Serum calcium levels in acutely infected cattle have been documented to fall to a mean of 7.84 ± 0.16 mg/dL, a level that directly contributes to the muscular stiffness, weakness, and recumbency that characterize the disease [39, 41].

The physiological underpinning of this hypocalcemia is not fully elucidated but is likely multifactorial, involving anorexia, renal loss, and potential sequestration. This electrolyte disturbance is a key driver of the musculoskeletal signs. The animal becomes stiff and lame, showing a characteristic reluctance to move, with a stilted, “walking on eggs” gait. The stiffness is most pronounced in the shoulders, neck, and back, and can be so severe as to cause recumbency for 24–72 hours [19, 24]. The term “stiff-sickness” is therefore highly descriptive. The severity of lameness is a key prognostic indicator; animals that are unable to rise have a significantly poorer outlook.

Musculoskeletal, Respiratory, and Neurological Pathology

The musculoskeletal signs are directly linked to the pathological findings. Upon necropsy, affected muscles often appear pale, edematous, and may contain focal areas of hemorrhage. This myopathy is not a primary viral myositis but rather a secondary consequence of the severe hypocalcemia and systemic inflammatory response, leading to muscle fiber degeneration and necrosis. The pathogenesis also involves the intense neutrophilia, as activated neutrophils can release proteolytic enzymes and reactive oxygen species that contribute to local tissue damage [39]. The severe stiffness and recumbency can lead to secondary complications, including pressure sores and nerve damage, further complicating recovery.

Respiratory pathology is a major contributor to severe disease and mortality. While many cases present with only tachypnea, a subset of animals develops a characteristic and ominous sign: subcutaneous emphysema [19]. This is a palpable “crackling” sensation under the skin over the neck, shoulders, and back, indicating that air has leaked from the respiratory tract into the subcutaneous tissues. At necropsy, the lungs in such cases show severe and extensive interstitial emphysema, with air-filled bullae visible on the pleural surface and within the interlobular septa. The airways are often filled with frothy, serosanguinous fluid, indicative of pulmonary edema [24, 27]. This pulmonary pathology is the result of increased vascular permeability and alveolar damage, likely driven by the virus-induced inflammatory cytokine storm. Damage to the alveolar epithelium allows air to dissect along the bronchovascular sheaths into the mediastinum and then into the subcutaneous tissues. This condition, combined with the loss of the swallowing reflex, places the animal at extreme risk for aspiration pneumonia, a common terminal event in fatal cases [24].

Neurological involvement, while less frequent, represents the most severe end of the disease spectrum. In mild cases, this may manifest as muscle tremors, hyperesthesia, and weakness. However, in severe, protracted cases, especially those seen in bulls or older, high-producing dairy cows, neurological signs can dominate. These include ataxia, paresis, and ascending paralysis, culminating in complete recumbency. In extreme instances, as documented with the isolation of the novel Hayes Yard virus from a bull, neurological signs can include profound paralysis and recumbency, necessitating euthanasia [27]. The pathological substrate for these signs is likely a combination of metabolic derangement (hypocalcemia), direct viral effects on the central nervous system, and vascular damage leading to focal hemorrhages within the spinal cord and brain. Histological examination of the spinal cord in such cases can reveal extensive hemorrhage in the dura mater with moderate perineuronal edema [27].

Gastrointestinal, Ocular, and Reproductive Signs

Ruminal stasis is a nearly universal finding, detected in a significant proportion of clinical cases [19]. The animal’s rumen is quiet, and there is often a palpable bloat. This is a direct consequence of the fever and systemic illness, as the smooth muscle of the rumen is profoundly affected by the electrolyte imbalances and systemic inflammation. The loss of the swallowing reflex, which occurs in severe cases, is a particularly grave sign, as it prevents the animal from clearing saliva and feed, leading to drooling and a high risk of aspiration [24].

Ocular signs are also common. Affected cattle often show a serous to mucopurulent ocular discharge, with congested and injected conjunctival blood vessels. Photophobia is frequently noted. These signs are part of the generalized congestion of mucous membranes and the febrile response.

Reproductive consequences are economically significant. Abortion can occur in pregnant cattle, reported in 6–41% of affected cases in some outbreak studies [19, 30]. The mechanism is likely related to the high fever and the severe systemic inflammatory response, which can compromise the placental blood supply and induce fetal stress. In lactating cows, there is a sudden and precipitous drop in milk production, which is the primary driver of economic loss [24, 30, 34]. Lactating cows can lose a substantial percentage of their daily milk yield, and this loss can persist for weeks after clinical recovery, leading to significant financial hardship for dairy producers [30]. In bulls, temporary or permanent infertility resulting from decreased libido and impaired spermatogenesis associated with the febrile episode is a documented concern.

The Acute Phase Response and Coinfections

The clinical syndrome is underpinned by a dramatic acute phase response (APR). Serum concentrations of positive acute phase proteins, including haptoglobin, serum amyloid A, and ceruloplasmin, are significantly elevated in infected cattle compared to healthy controls. Conversely, albumin, a negative acute phase protein, is significantly decreased [34]. This APR profile serves as a systemic biomarker of the severity of inflammation and tissue damage. Concurrently, there is a significant elevation in the pro-inflammatory cytokines interleukin-2 (IL-2) and interleukin-6 (IL-6), along with inflammatory biomarkers such as cortisol and C-reactive protein (CRP) [41]. This cytokine storm drives the fever, anorexia, and muscle catabolism characteristic of the disease. The profound hypercortisolemia contributes to the observed immunosuppression and lymphopenia [41].

The clinical picture can be significantly complicated by coinfection. A recent investigation in central China by Shi et al. found a high coinfection rate (44.3%) between BEFV and ‘Candidatus Mycoplasma haemobos’ in clinically ill cattle [44]. Crucially, 75% of the deceased cattle in that study were coinfected, suggesting that concurrent infection with this hemotropic mycoplasma may predispose animals to a more severe and fatal disease outcome. This finding underscores the importance of considering coinfections in the differential diagnosis and management of BEF outbreaks, particularly in regions where both pathogens are endemic.

Pathological Findings at Necropsy

Postmortem examination reveals a consistent set of gross and microscopic lesions that reflect the clinical signs. The carcass is often in good body condition, indicating an acute death, but may be dehydrated. The most striking finding is severe pulmonary edema and interstitial emphysema [24, 27]. The lungs are heavy, wet, and fail to collapse. Frothy fluid exudes from the cut surface of the trachea and bronchi. The subcutaneous and intermuscular tissues are edematous, and serous effusions are often present in the thoracic and abdominal cavities. Serosal hemorrhages, particularly on the epicardium, endocardium, and the surface of the rumen and abomasum, are frequently observed. The lymph nodes are enlarged, edematous, and congested. The muscles of the hindlimb and back may appear pale and waxy, indicative of myodegeneration. Histologically, the lung shows intense congestion, alveolar edema, and hyaline membrane formation. There is a marked infiltration of neutrophils into the alveolar septa and interstitium. This complex pathology, driven by endothelial damage and an exaggerated inflammatory response, distinguishes BEF from many other febrile illnesses of cattle and confirms the seriousness of this seemingly transient disease.

Epidemiology and Vector-Borne Transmission Dynamics

Bovine ephemeral fever virus (BEFV) exhibits a complex epidemiological profile characterized by pronounced seasonality, a broad but discontinuous global distribution, and a persistent, unresolved ambiguity regarding its primary arthropod vectors. As an arthropod-borne virus (arbovirus) classified within the genus Ephemerovirus, family Rhabdoviridae, BEFV is responsible for economically devastating outbreaks across tropical, subtropical, and warm temperate regions of Africa, Asia, the Middle East, and Australia [3, 24]. The virus has not been reported in the Americas or continental Europe, although the potential for introduction and establishment is considered a genuine threat due to changing climatic conditions and the ubiquity of competent vector species [30]. The epidemiology of BEFV is intrinsically linked to the biology, ecology, and population dynamics of its putative dipteran vectors, with disease occurrence exhibiting a distinct temporal pattern that mirrors periods of peak vector activity.

Global Distribution and Phylogenetic Lineages

Phylogenetic analyses of the viral glycoprotein (G) gene, the primary target for neutralizing antibodies and a key determinant of antigenic variation, have consistently delineated four major global lineages: the Middle Eastern, East Asian, Australian, and African lineages [2, 9, 28]. The East Asian lineage itself demonstrates substantial internal diversity, having been further subdivided into multiple sublineages, with evidence of a novel sublineage emerging in Southwest China and the first documented recombination events among East Asian isolates [9]. The Middle Eastern lineage has been identified as the predominant lineage circulating in Iran, Turkey, Israel, and, notably, during the 2018-2019 incursions in India, indicating a westward expansion of this clade [2, 14, 18, 49]. The Iranian viruses from the large 2020 epizootic clustered phylogenetically with Turkish isolates from the same period, yet no novel amino acid substitutions were identified in the G protein, suggesting that host factors, environmental conditions, or alterations in vector competence, rather than antigenic drift, were the primary drivers of that particular epizootic [2]. In India, the first complete genome of a BEFV isolate was characterized and found to belong to the Middle Eastern lineage, possessing 30 unique mutations, including 10 non-synonymous mutations in the P, L, and GNS proteins, which are predicted to alter protein structure and dynamics [14]. A virus from Central China (strain HN2437) showed significant divergence from these established lineages, suggesting unique evolutionary pressures and underscoring the need for continuous molecular surveillance to monitor vaccine efficacy [44]. The implications of this lineage diversity for cross-protection are profound, as evidenced by the periodic outbreaks in Turkey that have required consideration of vaccines containing viruses from different genetic clusters [50].

Host Range and Reservoir Hosts

While clinical disease is most frequently observed in cattle (Bos taurus and Bos indicus) and water buffalo (Bubalus bubalis), the host range of BEFV extends considerably beyond these primary domestic species [6, 13, 17]. Serological surveys have demonstrated exposure in a diverse array of wild and domestic ruminants. In the Republic of Korea, a seroprevalence of 10.8% was detected in farmed and free-ranging cervids, with older age and proximity to neighboring ruminant farms identified as significant risk factors for seropositivity, suggesting that deer may serve as important viral reservoirs [13]. Similarly, in South Korea, retrospective serological screening of sheep and goats revealed an overall seroprevalence of 14.3%, with a significant protective effect associated with routine insecticide application (Odds Ratio [OR] = 0.514), confirming that vector control measures can reduce viral transmission even in non-primary hosts [17]. In northern Australia, feral water buffaloes exhibited a BEFV seroprevalence of 15.1%, consistent with rates observed in cattle in the same region, indicating that these buffalo populations are actively involved in the virus’s maintenance cycle and must be considered in any regional surveillance or eradication strategy [6]. Conversely, a comprehensive survey in Israel over a decade-long period (2000-2009) found a very low prevalence (0.96%) of neutralizing antibodies in wild and semi-captive species, with positive samples exclusively from animals in areas of prior cattle outbreaks; this led the authors to conclude that these species likely do not serve as true reservoirs but rather are sporadic spillover hosts [31]. The clinical significance of BEFV in wild ruminants is poorly understood, but their role as sentinels for viral circulation, particularly in inter-epidemic periods, is undeniable. The World Organization for Animal Health (WOAH) recognizes the importance of understanding the sylvatic cycle of BEFV for effective disease control, as these populations can harbor the virus undetected.

Risk Factors for Infection

Numerous host-level and environmental factors modulate the risk of BEFV infection. A comprehensive study in Punjab, Pakistan, identified breed as the most significant intrinsic risk factor, with exotic cattle breeds showing a dramatically higher seroprevalence (76.67% by ELISA) compared to indigenous cattle (approximately 55-64%) and buffaloes (approximately 18-22.5%) [4]. This highlights the potential for severe economic losses when high-producing, susceptible breeds are introduced into endemic areas. Age is a consistently identified risk factor; seroprevalence increases with age, likely reflecting cumulative exposure over time. In Pakistan, the highest prevalence was noted in the 1-3 year age group, while in South Korean sheep and goats, older adults had significantly higher odds of seropositivity compared to younger animals (OR = 2.327) [4, 17]. A study in Egypt found that Friesian breeds and females were more susceptible, and that infection rates were higher in the hot months (19.23%) compared to non-hot months (6.41%), a pattern directly attributable to vector abundance [19]. Geographical location exerts a powerful influence on disease risk. Within South Korea, the likelihood of seropositivity in sheep and goats was significantly higher in southern provinces than in northern provinces (OR = 2.166), mirroring the latitudinal gradient in vector habitat suitability and temperature [17]. Similarly, in Turkey, a 12-year retrospective study documented an average seroprevalence of 39.82% across 3,008 samples, but with striking regional variation, from 56.51% in Şanlıurfa to just 26.53% in Kilis [46]. The year-to-year variation in prevalence was also dramatic, ranging from 96.69% in 2015 to a mere 10.12% in 2017, reflecting the punctuated, epizootic nature of BEF [46]. The type of housing also matters; commercial dairy farms in Pakistan exhibited a higher prevalence (52%) than non-commercial farms (38%), likely due to higher animal density and more frequent introduction of susceptible stock [4].

Vector-Borne Transmission Dynamics: The Enigmatic Vector

Despite decades of research and substantial circumstantial evidence, the definitive identity of the primary biological vectors for BEFV remains one of the most critical gaps in our understanding of its epidemiology. The virus is generally, but not universally, accepted to be transmitted by hematophagous dipterans, with biting midges of the genus Culicoides and mosquitoes of the genera Culex, Anopheles, and Aedes being the prime suspects [24, 30, 48]. The disease is seasonal, peaking in summer, autumn, and during monsoonal rains, coinciding precisely with periods of peak insect activity, but experimental proof of transmission from infected arthropod to naive vertebrate host has been elusive [48, 50].

Evidence from Experimental Vector Competence Studies

Controlled laboratory studies have yielded conflicting results, highlighting the complexity of vector-virus interactions. A landmark study by Stokes et al. (2020) tested several colony lines of mosquitoes (Aedes aegypti, Culex pipiens, and Culex quinquefasciatus) and a Culicoides midge (Culicoides sonorensis) for their ability to become infected with and transmit an Israeli strain of BEFV [48]. The results were striking. There was absolutely no evidence of BEFV replication or dissemination in any of the three mosquito species following oral feeding on a blood-virus suspension. However, the same study found that C. sonorensis was susceptible to oral infection, with 13 out of 170 individuals (7.6%) harboring BEFV RNA in their bodies and critically, 2 individuals showing the presence of viral RNA in their heads, indicative of a fully disseminated infection (oral susceptibility rate of 1.2%) [48]. Furthermore, all C. sonorensis inoculated intrathoracically showed robust viral replication over 5-7 days. Despite this clear evidence of vector competence (the ability to become infected and support viral replication), the authors were unable to demonstrate transmission to calves when infected C. sonorensis were allowed to feed on them [48]. This failure could be due to a low titer of virus in the salivary glands, a salivary gland barrier, or suboptimal experimental conditions, but it underscores the profound challenge of establishing in vivo transmission models and translating laboratory findings to field conditions.

Contradictory and Compounding Evidence

Further complicating the picture, a separate study in Israel provided evidence suggesting that Culex pipiens mosquitoes may, in fact, be competent vectors. Chizov-Ginzburg et al. (2023) detected BEFV RNA in Cx. pipiens for up to 14 days following oral infection using a highly sensitive nested-qPCR assay, and more provocatively, they found BEFV in the F1 progeny (eggs and larvae) of infected females, suggesting the possibility of vertical (transovarial) transmission [47]. If confirmed, vertical transmission would represent a critical mechanism for viral overwintering and persistence during periods when adult vectors are inactive and cattle are not available. The authors proposed that Cx. pipiens could serve as a reservoir host, maintaining the virus across seasons. This stands in direct opposition to the findings of Stokes et al., highlighting that vector competence is highly dependent on the specific virus isolate, the geographic origin and genotype of the vector population, and the interaction between these two factors.

Field Evidence and the Role of Ticks

Field-based molecular surveys have provided additional, and perhaps surprising, insights into potential vectors. A critical study in central China examined ticks collected from clinically ill and asymptomatic cattle during a BEF outbreak. Ticks of three species, Haemaphysalis longicornis, Rhipicephalus microplus, and Rhipicephalus sanguineus sensu lato, were found to harbor BEFV RNA. The infection rates were substantial: 46.8% in H. longicornis, 11.3% in R. microplus, and 18.8% in R. s. l. during the outbreak [44]. Crucially, engorged H. longicornis had significantly higher BEFV infection rates than unfed ticks, suggesting that ticks may acquire the virus through feeding on viremic cattle [44]. This is the first evidence from China implicating ticks as potential carriers, and it opens a new dimension in BEFV transmission ecology, challenging the traditional focus on dipteran vectors. The coinfection scenario is also illuminating. In the same study, 44.3% of clinically ill cattle were coinfected with BEFV and ‘Candidatus Mycoplasma haemobos’, a tick-borne haemoplasma, and all deceased cattle were BEFV-positive, with 75% coinfected. This association raises the hypothesis that tick-borne pathogens, or the tick bite itself, may exacerbate BEFV disease severity, or that the host's response to one pathogen facilitates infection by the other. The World Health Organization (WHO) and WOAH emphasize that understanding the full vector range is paramount for predicting disease emergence and implementing effective vector control strategies.

Temporal Dynamics and the Role of Climate

The epidemiology of BEFV is characterized by a multi-annual periodicity. Outbreaks in endemic regions tend to occur in cycles of 4-5 years, often following periods of unusually high rainfall and warm temperatures that favor vector breeding and shorten the extrinsic incubation period of the virus within the vector [30, 50]. In Israel, outbreaks have occurred almost every other year, with the farm-level economic impact being a function of outbreak severity and the timing of the event relative to the lactation cycle of dairy cows [30]. The virus exhibits a rapid, explosive spread within a naive herd, with morbidity rates reaching 80-100% [24]. The short, intense viremic phase in cattle (lasting 2-8 days) provides a narrow temporal window for vector infection, but the sheer abundance of cattle combined with a high vector-to-host ratio during outbreak conditions likely compensates for this [24, 45]. A SYBR green-based RT-qPCR assay has demonstrated that viral RNA can be detected in experimentally infected cattle as early as 1 day post-infection, peaking at 3-5 days and declining rapidly by 7-8 days [45]. This rapid kinetics reinforces the necessity for vectors to exhibit high population densities and feeding rates to sustain transmission. The diagnostic performance of tests used to identify these acute infections has been critically evaluated. In a South African study, virus isolation was found to be highly specific (99%) but poorly sensitive (30%), while clinical examination had a sensitivity of 86% and specificity of 67% in a high-prevalence population (67%) [1]. This indicates that in a real-world outbreak, many acute infections will be missed by laboratory testing, further emphasizing the reliance on sensitive vector surveillance for early warning.

The Threat of Emergence in Naive Regions

A profound implication of the global distribution of BEFV and the widespread presence of potential vectors like Culicoides sonorensis and Culicoides imicola is the real and present danger of its introduction into naive regions, most notably Europe and the Americas. The emergence of bluetongue virus (BTV) and Schmallenberg virus (SBV) in northern Europe over the past two decades serves as a stark precedent for the vulnerability of these ecosystems to novel arboviruses [30]. Modeling studies and risk assessments have identified that the European cattle population, which has zero herd immunity, would suffer catastrophic economic losses in the event of a BEFV introduction. These losses would not be limited to mortality and milk drop (which can affect farm income for months after the clinical phase) but would also include the costs of animal movement restrictions, trade embargoes, and culling [30]. The economic impact would be comparable to, if not greater than, the estimated billions of euros in damage caused by BTV and SBV. The fact that BEFV is already endemic in western Turkey, the Middle East, and parts of Asia places it on the doorstep of southeastern Europe. Continuous entomological and serological surveillance at these frontiers, coupled with rapid molecular diagnostics (such as the recombinase polymerase amplification [RPA] lateral-flow dipstick assay capable of detecting 8 copies per reaction [22]), is therefore not just a scientific exercise but a critical component of global biosecurity and livestock health management.

Laboratory Diagnostics and Diagnostic Performance Evaluation

The accurate and timely diagnosis of bovine ephemeral fever virus (BEFV) infection is a cornerstone of effective disease surveillance, outbreak response, and vaccination program management. However, the diagnostic landscape for BEFV is fraught with unique challenges stemming from the virus's transient viremia, the acute and self-limiting nature of clinical disease, and the significant logistical constraints present in many endemic regions, particularly across Africa and parts of Asia [1, 24]. The diagnostic arsenal for BEFV encompasses a spectrum of assays, ranging from field-based clinical examination and emerging rapid tests to sophisticated molecular and serological laboratory techniques. The performance characteristics of these assays, their sensitivity (Se), specificity (Sp), predictive values, and diagnostic utility in different epidemiological contexts, have been rigorously evaluated, revealing critical insights that inform their optimal application. This section provides a deep, mechanism-informed analysis of the performance of laboratory diagnostics for BEFV, interpreting test characteristics through the lens of viral pathogenesis and the host immune response.

Direct Pathogen Detection: Virological and Molecular Assays

The direct detection of BEFV or its components is essential for confirming acute infection, particularly during the short window of viremia, which typically spans only 2–8 days post-infection [24, 45]. The choices available for direct detection include classical virology, conventional and real-time polymerase chain reaction (PCR), and novel isothermal amplification technologies.

Virus Isolation. Historically considered a gold standard for definitive confirmation, virus isolation (VI) involves inoculating buffy coat samples from heparinized blood onto susceptible cell lines, such as baby hamster kidney (BHK-21) or Vero cells, and observing for characteristic cytopathic effect (CPE), followed by confirmatory electron microscopy or immunofluorescence [1, 7, 49]. As a test, VI is exquisitely specific. A Bayesian latent class analysis by Grobler et al. (2025) estimated the specificity of VI at 99% (95% PI: 97%; 100%) in a population of naturally infected South African cattle, confirming its unparalleled ability to rule in an infection when positive [1]. The biological basis for this high specificity lies in the requirement for a live, replication-competent virus that must be present at a sufficient titer to initiate a productive infection in cell culture. However, this biological requirement is also the source of its critical limitation: poor sensitivity. The same study reported a VI sensitivity of only 30% (95% PI: 20%; 44%) [1]. This abysmal sensitivity is mechanistically driven by the transient nature of BEFV viremia. By the time clinical signs, such as fever, stiff gait, and inappetence, are apparent, the peak of viremia may have already passed, and the virus may be rapidly cleared by the host's innate and adaptive immune responses. Furthermore, the virus is thermolabile, and its infectivity declines rapidly if samples are not collected into appropriate transport media (e.g., viral transport medium) and maintained under cold chain conditions (4°C to -80°C), a practical impossibility in many remote, resource-limited endemic areas [1, 24]. Therefore, while a positive VI result is diagnostic, a negative result cannot exclude BEFV infection, rendering it an impractical tool for frontline field diagnosis.

Conventional and Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR). Molecular detection of BEFV RNA has largely supplanted virus isolation for routine diagnosis due to its superior analytical sensitivity, faster turnaround time, and ability to detect non-infectious viral RNA. Several RT-PCR assays have been developed, targeting different genomic regions, most commonly the glycoprotein (G) gene and the RNA-dependent RNA polymerase (L) gene, with profoundly different performance characteristics [1, 45, 51]. The selection of the genetic target is not arbitrary; it directly impacts test accuracy due to the underlying evolutionary biology of the virus. The G gene, particularly the G1 neutralization epitope, is under significant immune-mediated selection pressure, leading to hypervariability in specific regions [2, 26, 50]. Consequently, an RT-PCR targeting a variable G gene region may fail to detect emerging strains that have accumulated mutations at primer binding sites, resulting in false-negative results. This was demonstrated by Grobler et al. (2025), who found that a G-gene conventional PCR had a sensitivity of 50% (PI: 38%; 61%) and specificity of 89% (PI: 75%; 98%) [1]. In contrast, an L-gene PCR, targeting the more conserved RNA-dependent RNA polymerase, significantly outperformed it, achieving a sensitivity of 64% (PI: 51%; 76%) and specificity of 96% (PI: 84%; 100%) [1]. The higher sensitivity of the L-gene assay is likely due to its ability to amplify a broader range of BEFV variants, including those from the Middle Eastern lineage and emerging East Asian sublineages [9, 23]. The moderate sensitivity of even the L-gene PCR (64%), however, underscores the diagnostic challenge of the short viremic window. Even with a highly conserved primer set, the assay can only detect virus if RNA is present in the sample at the time of collection. The analytical sensitivity of these assays can be enhanced using real-time quantitative RT-PCR (RT-qPCR) platforms. For instance, a SYBR Green I-based RT-qPCR assay developed by Gao et al. (2019) demonstrated a 100-fold higher analytical sensitivity compared to conventional RT-PCR, with intra- and inter-assay coefficients of variation of 0.23–0.89% and 0.23–1.02%, respectively [45]. This assay was able to detect BEFV RNA in experimentally infected cattle as early as 1 day post-infection (dpi) and as late as 7–8 dpi, peaking between 3–5 dpi, thus providing a reliable tool for profiling viral kinetics in vivo [45]. The World Organisation for Animal Health (WOAH) recognizes real-time RT-PCR as a prescribed test for the detection of virus in clinical samples, and its use is strongly recommended for confirmatory diagnosis. The comparative performance data make a compelling case for prioritizing L-gene or multi-target RT-PCR strategies over G-gene-only approaches to minimize the risk of false negatives due to genetic drift.

Isothermal Amplification and Point-of-Care Diagnostics. Given the infrastructure constraints (lack of thermocyclers, cold chain, and trained personnel) in many BEFV-endemic regions of Africa and Asia, there is an urgent, articulated need for robust and rapid pen-side diagnostics [1]. A promising solution is recombinase polymerase amplification (RPA), an isothermal nucleic acid amplification technology that operates at a constant temperature (typically 37–42°C) without the need for thermal cycling. Hou et al. (2017) developed an RPA assay combined with a lateral-flow dipstick (LFD-RPA) for the detection of the BEFV G gene [22]. This LFD-RPA assay was performed at 38°C for 20 minutes, with results visualized on a dipstick within 5 minutes. Critically, its analytical sensitivity was 8 copies per reaction, and it demonstrated a diagnostic coincidence rate of 96.09% (123/128) with real-time qPCR when tested on clinical specimens, a performance level that exceeded that of conventional RT-PCR [22]. The high specificity was confirmed by the absence of cross-reactivity with other major bovine viral pathogens, including bovine viral diarrhea virus (BVDV), infectious bovine rhinotracheitis virus (IBRV), and bovine coronavirus (BCoV) [22]. The biological principle underlying RPA’s utility is its tolerance to inhibitors often present in crude blood samples, which can plague traditional PCR. This, combined with its speed and minimal equipment requirements, positions LFD-RPA as a transformative tool for field-level outbreak investigations, allowing for rapid implementation of control measures (e.g., quarantine, insecticide application) before laboratory confirmation is even available.

Serological Diagnosis: Detecting Past Exposure and Vaccine Response

Serological assays detect antibodies generated by the host in response to BEFV infection or vaccination. These tests are invaluable for epidemiological surveillance, determining seroprevalence in a population, evaluating vaccine immunogenicity, and understanding herd immunity. Given the short viremic phase, serology often provides the only evidence of recent (or historical) viral circulation within a herd.

Virus Neutralization Test (VNT). The VNT, also known as the serum neutralization test (SNT), is the historical serological gold standard and is routinely used for international trade certification per WOAH guidelines. It detects neutralizing antibodies, primarily directed against the G1 epitope of the G protein, which correlate with protective immunity [4, 5, 25]. The VNT is highly specific because it relies on the functional inhibition of live virus infection in cell culture. In a Bayesian analysis conducted in Pakistan, the VNT showed a high seroprevalence in cattle (42%), which was statistically different from the ELISA result (45.6%, P = 0.001), indicating slight differences in diagnostic performance between the two platforms [4]. The VNT is also instrumental for assessing vaccine effectiveness. For instance, Gleser et al. (2024) used VNT to demonstrate that a four-dose vaccine regimen elicited significantly higher geometric mean titers (GMT = 4.45) compared to a two-dose regimen (GMT = 2.17), data that directly informed vaccination schedules [5]. Despite its value, the VNT is labor-intensive, requires live virus and cell culture facilities, and takes 5–7 days for results, making it unsuitable for high-throughput screening or rapid outbreak diagnosis.

Competitive and Blocking Enzyme-Linked Immunosorbent Assays (ELISAs). To overcome the limitations of VNT, several robust ELISA platforms have been developed, offering excellent throughput, speed, and safety. Benevenia et al. (2024) developed two competitive ELISAs (cELISAs) using monoclonal antibodies (mAbs) directed against either whole inactivated BEFV antigen or a recombinant nucleoprotein (N) [3]. The diagnostic sensitivity was 97.4% for the inactivated virus-based cELISA and 98.7% for the recombinant N-based cELISA, while both exhibited a diagnostic specificity of 100% [3]. These figures were derived from a large panel of 77 BEF-positive and 338 BEF-negative sera, providing robust evidence of their utility. This high specificity is expected, as competitive ELISAs are inherently resistant to cross-reactivity issues that can plague indirect ELISAs; the mAb competes for a single, specific epitope, reducing background. The high sensitivity of the recombinant N-based assay is mechanistically significant. The N protein is the most abundant and immunogenic viral protein, and antibodies to N appear early and persist in the host. Therefore, targeting N for serological detection provides a broader temporal window for seropositivity compared to assays relying solely on G protein epitopes. Blocking ELISAs, which function on a similar principle, have also been employed extensively, such as in the multi-year epidemiological surveillance study in Turkey by Tokgöz (2024), which screened over 3000 sera and found a 12-year average seropositivity of 39.82% [46]. ELISAs are the backbone of large-scale serosurveys, and the development of highly sensitive and specific recombinant antigen-based ELISAs represents a major advance for the global surveillance of BEFV.

Diagnostic Performance in Clinical Context: The Predictive Value Conundrum

The clinical utility of any diagnostic test is ultimately defined by its positive predictive value (PPV) and negative predictive value (NPV), which are profoundly influenced by the pre-test probability (disease prevalence). In the context of BEFV diagnosis, the performance characteristics of available assays create a problematic scenario for the field clinician, as elegantly demonstrated by the Bayesian analysis of Grobler et al. (2025) [1]. In their study population, which consisted of clinical suspects, the true prevalence of BEFV infection was estimated at 67% (PI: 52%; 81%). Within this high-prevalence context, the laboratory assays that performed well (L-gene PCR, VI) demonstrated excellent PPVs, meaning a positive test confidently confirms BEFV infection. However, the NPVs were poor. For example, the L-gene PCR had a sensitivity of only 64%. This means that even in a population where the disease is highly likely, a negative L-gene PCR does not rule out BEFV, one in three infected animals would be missed [1]. The situation is even worse for virus isolation (30% sensitivity). This "false negative" problem is not merely a statistical artifact but a direct consequence of BEFV pathogenesis: the virus is only present in the blood for a very short period, and the window for positive molecular detection is narrow and easily missed by a single sample collection.

This diagnostic gap has profound clinical implications. A field veterinarian faced with a febrile, stiff, and recumbent cow in an endemic area cannot rely on a negative PCR or VI result to discard BEF as a diagnosis. They must instead treat the case syndromically. The study authors concluded that the poor NPV of current laboratory tests "limit their usefulness to field veterinarians attempting to exclude BEF as diagnosis" [1]. This underscores the critical need for alternative diagnostic approaches. Clinical examination, though moderately specific (67%), demonstrated a relatively high sensitivity of 86%, indicating that an experienced veterinarian's judgment remains a valuable, if imperfect, diagnostic tool [1]. However, the ultimate solution lies in the development of novel pen-side diagnostics with drastically improved sensitivity (approaching 100%) to enable the rule-out of BEFV infection at the point of care. The LFD-RPA platform [22] represents a promising step in this direction, but its field validation for NPV in low- to moderate-prevalence settings remains to be performed. Until such sensitive, field-ready tools are available, the diagnosis of BEFV will continue to rely on a combination of astute clinical observation and the judicious, but cautious, interpretation of laboratory results.

Immune Response and Vaccination Strategies

The interplay between Bovine Ephemeral Fever Virus (BEFV) and the host immune system is a complex, dynamic battle that dictates the trajectory of infection, clinical outcome, and the efficacy of prophylactic interventions. Understanding these molecular and cellular mechanisms is paramount for the rational design of next-generation vaccines and antiviral therapeutics. This section provides an exhaustive analysis of the innate and adaptive immune responses to BEFV, the sophisticated viral countermeasures that subvert these defenses, and the current state and future directions of vaccination strategies against this economically devastating arbovirus.

Innate Immune Recognition and the Interferon Response

The initial host defense against BEFV hinges on the rapid detection of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs), leading to the induction of type I interferons (IFNs) and a subsequent antiviral state. The mitochondrial antiviral signaling protein (MAVS) serves as a central adaptor molecule in the retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) signaling pathway, which is critical for sensing BEFV RNA. Upon viral infection, MAVS is activated and orchestrates the downstream phosphorylation and nuclear translocation of interferon regulatory factors (IRFs), particularly IRF3 and IRF7, culminating in the transcription of IFN-β and IFN-stimulated genes (ISGs). The critical nature of this pathway is underscored by the multiple, convergent strategies BEFV has evolved to dismantle it. Research has demonstrated that BEFV infection triggers the upregulation of host proteins that act as potent negative regulators of MAVS. For instance, the mitochondrial single-stranded DNA-binding protein 1 (SSBP1) is induced during BEFV infection and acts as an essential negative regulator of MAVS [33]. Mechanistically, SSBP1 recruits the E3 ubiquitin ligase Smad ubiquitin regulatory factor 1 (Smurf1) to catalyze K48-linked polyubiquitination of MAVS, marking it for proteasomal degradation [33]. This effectively short-circuits the antiviral signaling cascade at its most critical juncture. Similarly, the receptor for activated C kinase 1 (RACK1) is also upregulated by BEFV and promotes the degradation of MAVS via the ubiquitin-proteasome system, but through a distinct E3 ligase, STIP1 homology and U-box containing protein 1 (STUB1) [35]. RACK1 enhances the interaction between STUB1 and MAVS, facilitating the latter's ubiquitination and subsequent degradation [35]. This functional redundancy, targeting MAVS through multiple independent pathways (SSBP1-Smurf1 and RACK1-STUB1), highlights the paramount importance of silencing MAVS-mediated signaling for successful BEFV replication.

Beyond the direct degradation of MAVS, BEFV also manipulates the downstream interferon regulatory factors. Interferon regulatory factor 8 (IRF8) is another host factor that is upregulated upon BEFV infection and, paradoxically, promotes viral replication [32]. The proviral effect of IRF8 is mediated through its suppression of the type I IFN signaling pathway. Specifically, IRF8 upregulates the expression of NEDD4 Like E3 ubiquitin ligase (NEDD4L), which then targets IRF9 for ubiquitin-proteasomal degradation [32]. IRF9 is a non-redundant component of the ISGF3 transcription factor complex (STAT1-STAT2-IRF9), which is essential for driving the expression of ISGs in response to IFN signaling. By degrading IRF9, BEFV effectively blunts the amplification loop of the IFN response, rendering cells more susceptible to infection. Furthermore, the virus employs microRNAs to fine-tune the host antiviral response. BEFV infection significantly upregulates miR-3470b, which directly targets the 3' untranslated region of MAVS mRNA, leading to translational repression and reduced MAVS protein levels [40]. This represents a non-canonical, post-transcriptional mechanism for suppressing the innate immune response. Collectively, these findings illustrate a multi-pronged viral assault on the MAVS-IRF axis, including transcriptional upregulation of host antagonists (SSBP1, RACK1, IRF8), induction of specific miRNAs (miR-3470b), and recruitment of distinct E3 ubiquitin ligases to degrade key signaling molecules.

Cellular Stress Responses and Autophagy in BEFV Pathogenesis

In addition to subverting the classical IFN pathway, BEFV intricately manipulates host cellular stress responses, particularly autophagy, to its advantage. Autophagy is a conserved catabolic process that can function as an antiviral defense mechanism by degrading viral components. However, many viruses have evolved to hijack this pathway for their own replication. BEFV is a master manipulator of autophagy, inducing a complete autophagic response that ultimately benefits viral replication [38]. The virus triggers autophagy through the simultaneous activation of the PI3K/Akt/NF-κB and Src/JNK/AP1 signaling pathways in the early to middle stages of infection [38]. A key event is the JNK-mediated phosphorylation of Bcl-2, which disrupts its inhibitory interaction with Beclin 1, a core component of the autophagy initiation complex [38]. At later stages of infection, BEFV suppresses the PI3K/Akt/mTOR pathway, a master negative regulator of autophagy, further promoting autophagic flux [38]. The viral matrix (M) protein has been identified as one of the viral proteins responsible for suppressing the mTORC1 pathway [38]. The induction of autophagy is not a bystander effect; it is essential for efficient virus production. Pharmacological inhibition of autophagy with 3-methyladenine (3-MA) or genetic knockdown of autophagy-related genes (ATGs) significantly reduces BEFV replication [38]. Furthermore, the formation of autolysosomes, the final degradative compartment of the autophagic pathway, is required for maximal virus yield, suggesting that BEFV may utilize the membrane components or catabolic products of autophagy for its replication cycle [38]. The therapeutic potential of targeting this pathway is evident, as drugs like aspirin and 5-aminoimidazole-4-carboxamide riboside (AICAR) have been shown to suppress BEFV replication by inhibiting the virus-induced autophagy cascade [42]. Aspirin directly suppresses the NF-κB pathway and reverses the BEFV-activated Src/JNK pathway, while AICAR transcriptionally downregulates ATG genes and enhances the proteasomal degradation of Atg7 [42].

Concurrently, BEFV infection triggers a senescence-like cellular response, particularly in cell culture systems used for vaccine production. Transcriptomic analysis of BEFV-infected BHK-21 cells revealed a gene expression signature consistent with cellular senescence [53]. This senescence-like state, characterized by markers such as increased senescence-associated β-galactosidase activity, was found to inhibit BEFV replication [53]. Subclones of BHK-21 cells exhibiting a high degree of senescence were less permissive to virus growth, and chemically inducing a senescence-like state with camptothecin rendered cells more resistant to infection [53]. This presents a unique challenge for industrial-scale vaccine manufacturing, where the host cell's antiviral response, including senescence, can dampen viral antigen yield. However, it also suggests that modulating the cellular state could be a strategy to control viral replication.

Humoral and Cell-Mediated Adaptive Immunity

The adaptive immune response is critical for clearing BEFV infection and providing long-term protection against reinfection. The humoral response, particularly the production of neutralizing antibodies against the viral glycoprotein (G protein), is considered the primary correlate of protection. The G protein is a class I transmembrane protein that forms the spikes on the virion surface and is responsible for receptor binding and membrane fusion. It contains four major neutralization sites (G1, G2, G3, and G4), with the G1 epitope being a dominant target for virus-neutralizing antibodies [20, 25]. The critical role of the G protein in eliciting protective immunity is the foundation for nearly all vaccine development efforts. The virus neutralization test (VNT) remains the gold standard for detecting protective antibodies, and seroprevalence studies consistently demonstrate that exposure or vaccination leads to the production of neutralizing antibodies [4, 7, 8]. For instance, in a field study in Israel, the highest titers of BEFV-neutralizing antibodies were found in cattle that were both vaccinated and naturally infected, indicating a potent anamnestic or booster response [8]. The duration of this humoral immunity is a key factor in vaccine efficacy, with studies showing that geometric mean titers (GMTs) of serum-neutralizing antibodies (SNAb) correlate with the number of vaccine doses administered [5].

While the humoral response is paramount, cell-mediated immunity, particularly cytotoxic T lymphocyte (CTL) responses, likely plays a significant role in controlling infection and clearing virus-infected cells. Immunoinformatic analyses of the BEFV G protein have identified several potential CTL epitopes, which are short peptide fragments presented by major histocompatibility complex (MHC) class I molecules [12]. These predicted epitopes, such as those within regions AA67-74, AA132-149, AA196-225, and AA315-456, are conserved across different BEFV strains and are strong candidates for inclusion in multi-epitope vaccines designed to stimulate both humoral and cellular arms of the immune system [12, 26]. Experimental evidence for the activation of a cellular response comes from studies using a recombinant subunit vaccine based on a truncated G protein (s510) produced in CHO cells. Vaccination of cattle with this antigen led to a significant upregulation of IFN-γ mRNA, a key cytokine produced by activated T cells and NK cells, supporting the induction of a Th1-biased immune response [52]. Similarly, a recombinant rabies virus (RABV) expressing the BEFV G protein (LBNSE-BG) was shown to activate more dendritic cells (DCs), B cells, and T cells in immunized mice compared to the parent virus, further confirming the immunogenicity of the G protein for both B and T cell compartments [54].

Vaccination Strategies: Current Landscape and Future Directions

Given the significant economic impact of BEF, vaccination is the cornerstone of disease control in endemic regions. The current landscape is dominated by traditional vaccine platforms, but a new wave of rationally designed candidates is emerging.

Inactivated and Live-Attenuated Vaccines: The most widely used commercial vaccines are inactivated (killed) and live-attenuated virus preparations. Inactivated vaccines, such as those used in Japan and Egypt, are safe and have been shown to induce protective antibody responses in calves [11, 51]. However, they often require multiple doses and adjuvants to achieve robust and long-lasting immunity. The choice of adjuvant is critical; studies have shown that a mixture of saponin and Carbopol (a cross-linked polyanionic polymer) as a diluent for a freeze-dried BEF vaccine significantly enhances the humoral immune response compared to saponin alone, inducing higher neutralizing antibody titers and longer-lasting immunity [57]. Live-attenuated vaccines, such as the widely used strain 919-based vaccine (Ultravac®, Zoetis™) in Israel and Australia, are generally more potent and require fewer doses. The South African live-attenuated vaccine, derived from a local field strain, has also been a mainstay of control in that region [15]. However, concerns regarding safety, potential for reversion to virulence, and genetic instability persist. A landmark field effectiveness study of the 919 strain vaccine during a real-world outbreak in Israel demonstrated a moderate vaccine effectiveness (VE) of 60% for preventing clinical disease [8]. Importantly, a non-statistically significant trend towards protection from mortality was observed, with no deaths in the vaccinated group compared to 2.61% mortality in unvaccinated cattle [8]. This study highlighted that while the vaccine is beneficial, its effectiveness is not absolute.

Optimizing Vaccination Regimens: The moderate effectiveness of existing vaccines has spurred research into optimizing vaccination schedules to maximize protective immunity. A retrospective cohort study analyzing different vaccination regimens for the 919 strain vaccine revealed a clear dose-dependent effect on VE and antibody titers [5]. Compared to no vaccination, the VE was 39% for two doses, 66% for three doses, and 82% for four doses [5]. This was corroborated by serology, with the four-dose regimen yielding the highest GMT of SNAb (4.45), followed by three doses (3.53) and two doses (2.17) [5]. Based on these findings, a recommended protocol involves vaccinating calves as early as four to six months old with two doses spaced one month apart, followed by a third and even fourth dose administered six to 12 months later, ideally just before the high-risk vector season [5]. This strategy aims to build and maintain a high level of population immunity, especially in high-challenge environments.

Next-Generation Vaccine Candidates: To overcome the limitations of traditional vaccines, including production difficulties, cost, and safety concerns, several next-generation platforms are under active investigation.

1. Subunit Vaccines: The G protein is the primary target for subunit vaccine development. A major challenge has been producing the full-length G protein, which is membrane-anchored and difficult to purify. Researchers have overcome this by creating truncated, secreted forms of the G protein (GΔTM) that lack the transmembrane domain. These secreted proteins can be produced in various expression systems. A recombinant GΔTM protein produced in mammalian stable cells was shown to be immunogenic in guinea pigs, eliciting virus-neutralizing antibodies [55]. Similarly, a GΔTM protein expressed in insect cells using a baculovirus system also induced neutralizing antibodies in immunized animals [58]. A particularly promising candidate is the s510 protein, a truncated G protein produced in the ExpiCHO™ mammalian expression system [52]. This recombinant protein, when formulated with adjuvant, stimulated an average 35-fold increase in neutralizing antibodies in cattle after three doses and induced significant IFN-γ mRNA expression, indicating a robust cellular response [52]. These results position the s510 protein as a leading candidate for a safe and effective subunit vaccine.

2. DNA Vaccines: DNA vaccines offer advantages in terms of stability, ease of production, and the ability to induce both humoral and cellular immunity. A plasmid DNA vaccine encoding the G1 epitope of the BEFV G glycoprotein (pcDNA3.1-G1) was evaluated in mice [25]. The construct successfully expressed the G1 protein in vitro and, upon intramuscular injection into mice, elicited specific antibodies that could neutralize BEFV in a VNT [25]. While the antibody titers were lower than those induced by a conventional inactivated vaccine, this study provides proof-of-concept that a DNA vaccine approach is feasible for BEF.

3. Recombinant Viral Vector Vaccines: Using a safe viral vector to deliver BEFV antigens is a highly effective strategy. A recombinant Newcastle disease virus (NDV) expressing the BEFV G protein (rL-BEFV-G) was constructed and evaluated [56]. This recombinant virus remained non-virulent in poultry and mice but triggered a high titer of neutralizing antibodies against BEFV in both species [56]. More recently, a recombinant rabies virus (RABV) expressing the BEFV G protein (LBNSE-BG) was developed as a potential bivalent vaccine [54]. This construct induced robust neutralizing antibodies against both BEFV and RABV in mice and provided complete protection against a lethal RABV challenge [54]. The LBNSE-BG vaccine also activated dendritic cells, B cells, and T cells more effectively than the parent RABV vector, suggesting a strong immunostimulatory profile [54]. Such a bivalent vaccine would be highly cost-effective and practical for use in regions where both BEF and rabies are endemic.

4. Multi-Epitope Vaccines: Advances in immunoinformatics have enabled the rational design of multi-epitope vaccines that incorporate multiple B-cell, CTL, and T-helper (Th) cell epitopes from the G protein [12]. By selecting conserved epitopes that are not subject to high mutation rates, these vaccines aim to provide broad protection against diverse BEFV lineages. A multi-epitope construct designed from regions of the G protein lacking genomic diversity has been proposed as a universal vaccine candidate [12]. While still in the in silico design phase, such approaches hold promise for developing vaccines that are less susceptible to antigenic drift.

The Challenge of Antigenic Diversity and Vaccine Efficacy

A significant hurdle for BEFV control is the genetic and antigenic diversity of circulating strains. Phylogenetic analyses have consistently classified global BEFV isolates into four major lineages: East Asia, Middle East, Australia, and Africa [2, 9, 14]. Within these lineages, further sub-lineages exist, and recombination events have been detected, particularly among East Asian strains, contributing to viral evolution [9, 10]. The emergence of novel sublineages, such as the one identified in Southwest China (sublineage 2), and the detection of unique amino acid substitutions in neutralizing epitopes (e.g., H51Y in the G3 epitope of an Iranian isolate from 2022) raise concerns about vaccine escape [2, 9]. For instance, the Middle Eastern lineage has replaced previously circulating East Asian BEFVs in Iran, and the vaccine strain used in a region may not be optimally matched to the circulating field strain [2]. This antigenic mismatch is a plausible explanation for the moderate (60%) effectiveness observed with the Australian 919 strain vaccine in Israel, where the circulating virus belongs to the Middle Eastern lineage [8, 28]. Continuous molecular surveillance is therefore essential to monitor the emergence of new variants and to inform the selection or update of vaccine strains. The World Organisation for Animal Health (WOAH) recognizes BEF as a notifiable disease due to its transboundary nature and economic impact, underscoring the need for coordinated global surveillance and vaccination strategies. The risk of BEFV emergence in naive regions, such as Europe, is a growing concern, driven by climate change expanding the range of arthropod vectors [30]. The European cattle population is immunologically naive, and an incursion could cause catastrophic economic losses, as seen with the emergence of bluetongue virus (BTV) and Schmallenberg virus (SBV) in the past two decades [30].

Genetic Diversity and Evolutionary Dynamics of BEFV

The genetic landscape of Bovine Ephemeral Fever Virus (BEFV) is characterized by a complex interplay of lineage diversification, geographic segregation, and ongoing molecular evolution that directly impacts viral fitness, antigenicity, and the efficacy of control measures. As a negative-sense, single-stranded RNA virus belonging to the genus Ephemerovirus within the family Rhabdoviridae, BEFV possesses a genome of approximately 14.9 kilobases that encodes five structural proteins (N, P, M, G, and L) and several accessory proteins (α1, α2, α3, β, and γ) [14, 21, 27]. The error-prone nature of the RNA-dependent RNA polymerase (RdRp), encoded by the L gene, serves as the primary engine of genetic variation, generating a standing pool of mutants upon which natural selection, genetic drift, and population bottlenecks act [10, 59]. This inherent mutability, combined with the vector-borne transmission cycle and the movement of livestock, has driven the emergence of four major phylogenetic lineages: the East Asian, Australian, Middle Eastern, and African lineages [2, 9, 18]. The delineation of these lineages is most frequently based on sequence analysis of the G glycoprotein gene, the primary target of neutralizing antibodies and a major determinant of viral tropism and immunogenicity [2, 9, 23, 49].

Phylogenetic Lineages and Global Phylogeography

Phylogenetic analyses of BEFV isolates from across the globe have consistently resolved a robust topology that reflects both historical divergence and contemporary dispersal patterns. The East Asian lineage is the most genetically diverse, encompassing isolates from Japan, China, Taiwan, South Korea, and Thailand [9, 23, 51]. Within this lineage, further subdivision into at least four distinct sublineages has been proposed, with sublineage 2 containing a novel cluster of recent isolates from Southwest China, including the BEFV/CQ1/2022 strain [9]. This high degree of intra-lineage diversity suggests a long history of endemic circulation and independent evolution within the region, potentially driven by the diversity of local vector populations and host movement patterns. The Australian lineage, represented by the vaccine strain 919 and field isolates, forms a distinct clade that has been historically isolated from the East Asian viruses, although recent evidence suggests occasional incursions or shared ancestry [5, 8, 27]. The Middle Eastern lineage is particularly noteworthy for its expansive geographic range, having been detected in Turkey, Israel, Iran, Egypt, and, more recently, India [2, 14, 18, 21, 49, 50]. The emergence of this lineage in South Asia is a relatively recent phenomenon. For instance, the first complete genome of an Indian BEFV isolate, obtained from outbreaks in 2018-2019, revealed a close phylogenetic relationship with Middle Eastern strains from Turkey (Ad12/TUR) and Israel (Israel 2006), confirming a westward-to-eastward expansion of this lineage [14, 18]. This displacement of previously circulating East Asian strains in Iran between 2012 and 2013 by the Middle Eastern lineage underscores the dynamic nature of BEFV phylogeography and the potential for lineage replacement events [2]. The African lineage, while less extensively sequenced, includes isolates from South Africa and is genetically distinct, forming a basal clade relative to the other lineages [15].

Mechanisms of Genetic Diversity: Mutation, Recombination, and Codon Usage

The generation of genetic diversity in BEFV is not solely reliant on point mutations. Recombination, a process often considered rare in negative-sense RNA viruses, has been documented in BEFV. A comprehensive analysis of BEFV genes G, M, N, and P detected recombination signals exclusively in the G and P genes [10]. Furthermore, genomic analysis of the novel sublineage from Southwest China provided the first evidence of recombination among East Asian BEFV isolates, suggesting that this mechanism may play a more significant role in shaping viral diversity than previously appreciated [9]. The functional consequences of these recombination events, such as the potential for antigenic shift or the acquisition of novel host-range determinants, remain an area of active investigation.

Codon usage bias analysis provides another layer of insight into the evolutionary pressures acting on BEFV. A detailed study of the G, M, N, and P genes revealed a moderate codon usage bias, with effective number of codons (eNC) values ranging from 42.99 to 47.10 [10]. This indicates that while mutation pressure is a factor, natural (translational) selection is the dominant force shaping codon usage patterns across these genes. The observed abundance of nucleotide A in all selected genes and the results from neutrality and parity rule 2 (PR-2) plots further support the conclusion that selection pressure, rather than mutational bias alone, is the primary driver of BEFV evolution [10]. This strong selection pressure likely reflects the need for the virus to optimize its replication and gene expression within the specific cellular environments of its bovine and insect hosts.

Antigenic Variation and Its Implications for Vaccine Efficacy

The G glycoprotein is the major target of the host humoral immune response, and its genetic variability has direct implications for vaccine efficacy. The G protein contains four major neutralizing epitopes (G1, G2, G3, and G4), and mutations within these regions can lead to antigenic drift, potentially allowing the virus to escape vaccine-induced immunity [2, 12, 20, 25]. A study of Iranian BEFVs spanning 2015 to 2022 identified a novel amino acid substitution, H51Y, within the G3 epitope in a strain from the 2022 outbreak in Kermanshah [2]. While this substitution did not appear to be associated with a major antigenic shift, it highlights the ongoing evolution of neutralizing epitopes. Similarly, comparative genomic analyses of the first Indian BEFV isolate revealed 30 unique mutations, including 10 non-synonymous mutations in the P, L, and GNS proteins, with in-silico assessments predicting alterations in protein structure and dynamics [14]. The GNS protein, a second glycoprotein unique to ephemeroviruses, also harbors antigenic sites, and its variability may contribute to immune evasion [14, 16]. The practical consequence of this antigenic diversity is that vaccines developed from one lineage may offer suboptimal protection against heterologous strains. For example, the live attenuated vaccine based on the Australian 919 strain has shown a vaccine effectiveness of only 60% in Israeli herds, which are exposed to the Middle Eastern lineage [8]. This moderate effectiveness, while beneficial, underscores the need for vaccines that incorporate antigens from locally circulating strains or that target conserved, immunodominant epitopes. The identification of cytotoxic T lymphocyte (CTL) epitopes within the G protein that are conserved across different BEFV strains offers a promising avenue for developing broadly protective vaccines [12].

Evolutionary Dynamics in the Context of Vector-Borne Transmission

The evolutionary trajectory of BEFV is inextricably linked to its transmission by arthropod vectors, primarily Culicoides biting midges and mosquitoes [44, 47, 48]. The virus must replicate efficiently in both its mammalian host and its insect vector, a dual-host lifestyle that imposes unique selective pressures. The genetic bottleneck imposed during vector transmission can lead to the rapid fixation of certain mutations, a phenomenon known as the "vector-borne transmission bottleneck." The recent discovery of BEFV RNA in Haemaphysalis longicornis, Rhipicephalus microplus, and Rhipicephalus sanguineus sensu lato ticks in China [44] adds a new dimension to the vector-host evolutionary dynamic. If ticks are confirmed as competent biological vectors, the prolonged feeding periods and transstadial transmission capabilities of ticks could provide a mechanism for BEFV overwintering and long-term maintenance, potentially altering the tempo and mode of viral evolution. The finding that engorged H. longicornis had significantly higher BEFV infection rates than unfed ticks suggests that the virus may replicate within the tick, a hallmark of biological transmission [44]. Furthermore, the detection of BEFV in Culex pipiens eggs and subsequent developmental stages under experimental conditions suggests the possibility of vertical transmission in mosquitoes, which could provide a mechanism for viral persistence during inter-epidemic periods [47]. These complex vector-virus interactions create a dynamic evolutionary landscape where mutations that enhance replication in one host may be deleterious in the other, leading to a finely balanced adaptation. The emergence of novel lineages, such as the distinct evolutionary profile of the HN2437 strain from central China [44], may reflect adaptation to local vector species or ecological niches, underscoring the need for continuous genomic surveillance in both livestock and vector populations.

References

[1] Grobler M, Fosgate GT, Swanepoel R, Crafford JE. A Bayesian latent class estimation of the diagnostic accuracy of clinical examination and laboratory assays to identify bovine ephemeral fever virus infection in South African cattle.. Preventive Veterinary Medicine. 2025. DOI: https://doi.org/10.1016/j.prevetmed.2025.106475

[2] Naderian A, Bakhshesh M, Ebrahimi-Jam MH. Molecular epizootiology of bovine ephemeral fever virus in Iran during 2015 to 2022. Veterinary Research Forum. 2025. DOI: https://doi.org/10.30466/vrf.2025.2040560.4446

[3] Benevenia R, Lelli D, Moreno A, Lavazza A, Kapri-Pardes E, Klement E, et al.. Development of two competitive ELISAs based on monoclonal antibodies for the serological detection of Bovine ephemeral fever virus.. Journal of Virological Methods. 2024. DOI: https://doi.org/10.1016/j.jviromet.2024.115009

[4] Nadeem S, Aslam R, Sajjad-ur-Rahman, Khan MK. Risk analysis and seroprevalence of bovine ephemeral fever virus in Punjab, Pakistan. Veterinární Medicína. 2024. DOI: https://doi.org/10.17221/95/2023-VETMED

[5] Gleser D, Cohen M, Kenigswald G, Kedmi M, Sharir B, Klement E. Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac®, Zoetis™): Evaluation of dose-dependent effectiveness and long-term immunity.. Vaccine. 2024. DOI: https://doi.org/10.1016/j.vaccine.2024.126531

[6] Adamu A, Hoskins AJ, Firth C, Gummow B, Hickson R, Horwood P. Serological Evidence of Akabane, Bluetongue, and Bovine Ephemeral Fever Virus Exposure in Feral Water Buffaloes from Northern Australia. Viruses. 2026. DOI: https://doi.org/10.3390/v18030363

[7] Tokgoz B, Tokgoz E, Sözmen M, Avcı O, Ütük A. Prevalence, isolation and molecular characterization of Bovine Ephemeral Fever Virus in south and southeast regions of Turkey in the outbreak of 2020. Journal of the Hellenic Veterinary Medical Society. 2024. DOI: https://doi.org/10.12681/jhvms.31543

[8] Gleser D, Spinner K, Klement E. Effectiveness of the strain 919 bovine ephemeral fever virus vaccine in the face of a real-world outbreak: A field study in Israeli dairy herds.. Vaccine. 2023. DOI: https://doi.org/10.2139/ssrn.4370261

[9] Chen J, Liu M, Li Y, Yang L, Tang Y, Dan R, et al.. Emergence and genomic analysis of a novel sublineage of bovine ephemeral fever virus in Southwest China. Frontiers in Microbiology. 2023. DOI: https://doi.org/10.3389/fmicb.2023.1161287

[10] Rani S, Mamathashree M, I UB, Patil SS, Krishnamoorthy P, Shueb M, et al.. Comprehensive examination on codon usage bias pattern of the Bovine Ephemeral fever virus. Journal of Biomolecular Structure and Dynamics. 2023. DOI: https://doi.org/10.1080/07391102.2023.2258220

[11] Otomaru K, Miyahara T, Saita H, Usa A, Ijiri M. Evaluation of antibody response to inactivated bovine ephemeral fever virus vaccine for Japanese Black calves in the field.. Animal science journal = Nihon chikusan Gakkaiho. 2023. DOI: https://doi.org/10.1111/asj.13904

[12] Mollazadeh S, Bakhshesh M, Keyvanfar H, Brujeni GN. Identification of Cytotoxic T lymphocyte (CTL) Epitope and design of an immunogenic multi-epitope of Bovine Ephemeral Fever Virus (BEFV) Glycoprotein G for Vaccine Development.. Research in Veterinary Science. 2022. DOI: https://doi.org/10.1016/j.rvsc.2021.12.023

[13] Yeh J, Ga YJ. Role of cervids in the epidemiology of bovine ephemeral fever virus infection in the Republic of Korea: A cross‐sectional retrospective study. Veterinary Medicine and Science. 2022. DOI: https://doi.org/10.1002/vms3.970

[14] Pyasi S, Gupta A, Hegde N, Nayak D. Complete genome sequencing and assessment of mutation-associated protein dynamics of the first Indian bovine ephemeral fever virus (BEFV) isolate. Veterinary Quarterly. 2021. DOI: https://doi.org/10.1080/01652176.2021.1995909

[15] Mlingo T, Nthangeni B, Mokoena NB. Genome sequence of Bovine Ephemeral fever virus vaccine strain of South African origin. Veterinary Medicine and Science. 2021. DOI: https://doi.org/10.1002/vms3.517

[16] Lo Y, Tulloch F, Wu H, Luke G, Ryan M, Chu C. Expression and immunogenicity of secreted forms of bovine ephemeral fever virus glycoproteins applied to subunit vaccine development. Journal of Applied Microbiology. 2021. DOI: https://doi.org/10.1111/jam.15044

[17] Hwang J, Ga YJ, Yeh J. Epidemiological Assessment of Risk Factors Associated with Bovine Ephemeral Fever Virus Exposure among Sheep and Goats in South Korea. Acta Scientiae Veterinariae. 2021. DOI: https://doi.org/10.22456/1679-9216.111679

[18] Pyasi S, Sahu B, Sahoo P, Dubey P, Sahoo N, Byrareddy S, et al.. Identification and phylogenetic characterization of bovine ephemeral fever virus (BEFV) of Middle Eastern lineage associated with 2018-2019 outbreaks in India.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13531

[19] El-Allawy T, Mahmoud FS, Malek S. EPIDEMIOLOGICAL STUDY ON BOVINE EPHEMERAL FEVER VIRUS (BEFV) INFECTION IN CATTLE AND BUFFALOES IN EGYPT. Assiut veterinary medical journal. 2021. DOI: https://doi.org/10.21608/avmj.2021.102772.1039

[20] Hou P, Zhao G, He C, Wang H, He H. Biopanning of polypeptides binding to bovine ephemeral fever virus G1 protein from phage display peptide library. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-017-1315-x

[21] Dorey-Robinson D, Marco MFd, Hernández-Triana L, Folly AJ, McElhinney L, Stokes J, et al.. Complete Genome Sequence of a Bovine Ephemeral Fever Virus Isolate from Israel. Microbiology Resource Announcements. 2019. DOI: https://doi.org/10.1128/MRA.00822-19

[22] Hou P, Zhao G, Wang H, He C, Huan Y, He H. Development of a recombinase polymerase amplification combined with lateral-flow dipstick assay for detection of bovine ephemeral fever virus. Molecular and Cellular Probes. 2017. DOI: https://doi.org/10.1016/j.mcp.2017.12.003

[23] Chaisirirat T, Sangthong P, Arunvipas P, Petcharat N, Thangthamniyom N, Chumsing W, et al.. Molecular characterization of bovine ephemeral fever virus in Thailand between 2013 and 2017.. Veterinary Microbiology. 2018. DOI: https://doi.org/10.1016/j.vetmic.2018.10.013

[24] Pyasi S, Sahu NR, Mohanty U, Nayak D. Bovine ephemeral fever: From underestimated illness to emerging threat - A review of pathogenesis, economic impact, and future control strategies.. Research in Veterinary Science. 2025. DOI: https://doi.org/10.1016/j.rvsc.2025.105904

[25] Pasandideh R, Shapouri MRSA, Nassiri MTB. Immunogenicity of a plasmid DNA vaccine encoding G1 epitope of bovine ephemeral fever virus G glycoprotein in mice. Onderstepoort Journal of Veterinary Research. 2018. DOI: https://doi.org/10.4102/ojvr.v85i1.1617

[26] Bakhshesh M, Ranjbar M, Almasi S. Immunoinformatic analysis of glycoprotein from bovine ephemeral fever virus. Biomedical and Biotechnology Research Journal (BBRJ). 2018. DOI: https://doi.org/10.4103/bbrj.bbrj_71_18

[27] Blasdell K, Davis S, Voysey R, Bulach D, Middleton D, Williams S, et al.. Hayes Yard virus: a novel ephemerovirus isolated from a bull with severe clinical signs of bovine ephemeral fever is most closely related to Puchong virus. Veterinary Research. 2020. DOI: https://doi.org/10.1186/s13567-020-00781-1

[28] Marco M, Hernández-Triana L, Dorey-Robinson D, McElhinney L, Sanders C, Carpenter S, et al.. Phylogenetics and vector competence of a bovine ephemeral fever virus strain from Israel. Access Microbiology. 2019. DOI: https://doi.org/10.1099/ACMI.AC2019.PO0362

[29] Della-porta A, Snowdon W. bovine ephemeral fever virus. CABI Compendium. 2018. DOI: https://doi.org/10.1201/9781351076401-8

[30] Lavon Y, Ezra E, Friedgut O, Behar A. Economic Aspects of Bovine Ephemeral Fever (BEF) Outbreaks in Dairy Cattle Herds. Veterinary Sciences. 2023. DOI: https://doi.org/10.3390/vetsci10110645

[31] Aziz-Boaron O, Brettschneider S, King R, Gelman B, Klement E. Seroprevalence of bovine ephemeral fever virus in domesticated and wildlife species during epidemic and inter-epidemic periods (2000-2009) in Israel.. Transboundary and Emerging Diseases. 2015. DOI: https://doi.org/10.1111/tbed.12104

[32] Hou P, Chen J, Zhu H, Yao X, Gao Z, Li Y, et al.. IRF8 facilitates bovine ephemeral fever virus replication by downregulating IRF9.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110597

[33] Li X, Song X, Ma X, Ma W, Gao S, Shi L, et al.. SSBP1 promotes bovine ephemeral fever virus replication by antagonizing antiviral immune responses via degrading MAVS.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110684

[34] Paksoy N, Balıkçı C, Merhan O, Dinçer E, Şahan A, Bozukluhan K. Evaluation of acute phase response in cattle with naturally infected bovine ephemeral fever virus. Acta Veterinaria Brno. 2024. DOI: https://doi.org/10.2754/avb202493020129

[35] Zhang Y, Hou P, He D, Wang H, He H. RACK1 degrades MAVS to promote bovine ephemeral fever virus replication via upregulating E3 ubiquitin ligase STUB1.. Veterinary Microbiology. 2021. DOI: https://doi.org/10.1016/j.vetmic.2021.109096

[36] Jiang H, Hou P, He H, Wang H. Cell apoptosis regulated by interaction between viral gene alpha 3 and host heterogeneous nuclear ribonucleoprotein K facilitates bovine ephemeral fever virus replication.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2019.108510

[37] Chen L, Li X, Wang H, Hou P, He H. Annexin A2 gene interacting with viral matrix protein to promote bovine ephemeral fever virus release. Journal of Veterinary Sciences. 2020. DOI: https://doi.org/10.4142/jvs.2020.21.e33

[38] Cheng C, Tseng H, Chiu H, Chang C, Nielsen B, Liu H. Bovine ephemeral fever virus triggers autophagy enhancing virus replication via upregulation of the Src/JNK/AP1 and PI3K/Akt/NF-κB pathways and suppression of the PI3K/Akt/mTOR pathway. Veterinary Research. 2019. DOI: https://doi.org/10.1186/s13567-019-0697-0

[39] Abdullah SW, Khan M, Aslam A, Masood S, Bajwa A, Sheikh AA. Detection of Bovine Ephemeral Fever Virus and Its Effects on Blood Parameters and Serum Calcium Levels in Cattle Population of District Swabi, Pakistan. Indian Journal of Animal Research. 2020. DOI: https://doi.org/10.18805/ijar.b-1019

[40] Hou P, Wang H, Zhao G, Hu G, Xia X, He H. MiR-3470b promotes bovine ephemeral fever virus replication via directly targeting mitochondrial antiviral signaling protein (MAVS) in baby hamster Syrian kidney cells. BMC Microbiology. 2018. DOI: https://doi.org/10.1186/s12866-018-1366-6

[41] Abo-Sakaya R, Bazán N. Molecular detection of novel bovine Ephemeral fever Virus strain and its effect on immune system in cattle, Egypt 2017. . 2020. DOI: https://doi.org/10.21608/bvmj.2020.26385.1193

[42] Tseng H, Huang W, Cheng C, Chiu H, Liao T, Nielsen B, et al.. Aspirin and 5-Aminoimidazole-4-carboxamide Riboside Attenuate Bovine Ephemeral Fever Virus Replication by Inhibiting BEFV-Induced Autophagy. Frontiers in Immunology. 2020. DOI: https://doi.org/10.3389/fimmu.2020.556838

[43] Cheng C, Huang W, Chi P, Chiu H, Liu H. Cell entry of bovine ephemeral fever virus requires activation of Src‐JNK‐AP1 and PI3K‐Akt‐NF‐κB pathways as well as Cox‐2‐mediated PGE2/EP receptor signalling to enhance clathrin‐mediated virus endocytosis. Cellular Microbiology. 2015. DOI: https://doi.org/10.1111/cmi.12414

[44] Shi H, Lv T, Zhang Z, Zhai H, Wang L, Ji S, et al.. Coinfection of Bovine ephemeral fever virus and ‘Candidatus Mycoplasma haemobos’ in cattle in Central China: implications for tick-borne transmission and viral divergence. BMC Veterinary Research. 2025. DOI: https://doi.org/10.1186/s12917-025-04917-3

[45] Gao S, Du J, Tian Z, Niu Q, Huang D, Wang J, et al.. A SYBR green I–based quantitative RT-PCR assay for bovine ephemeral fever virus and its utility for evaluating viral kinetics in cattle. Journal of Veterinary Diagnostic Investigation. 2019. DOI: https://doi.org/10.1177/1040638719895460

[46] Tokgöz BS. 2012-2023 Yılları Arasında Anti-Bovine Ephemeral Fever Virus Antikorlarının Yaygınlığına Dair Retrospektif Bir Çalışma. Etlik Veteriner Mikrobiyoloji Dergisi. 2024. DOI: https://doi.org/10.35864/evmd.1562972

[47] Chizov-Ginzburg A, Stram Y, Rot A, Taub-Umansky L, Izhaki O, Behar A. Stretching the wings further- susceptibility of Culex pipiens Linnaeus to bovine ephemeral fever virus infection under experimental conditions.. Acta Tropica. 2023. DOI: https://doi.org/10.1016/j.actatropica.2023.106995

[48] Stokes J, Darpel K, Gubbins S, Carpenter S, Marco MFd, Hernández-Triana L, et al.. Investigation of bovine ephemeral fever virus transmission by putative dipteran vectors under experimental conditions. Parasites & Vectors. 2020. DOI: https://doi.org/10.1186/s13071-020-04485-5

[49] Kasem S, Alkhalefa N, Magouz A, Ebrahem B, Khodier M, Abdo W, et al.. PHYLOGENETIC ANALYSIS OF BOVINE EPHEMERAL FEVER VIRUS ISOLATED FROM EGYPTIAN OUTBREAKSIN (2013 TO 2016). . 2020. DOI: https://doi.org/10.21608/kvmj.2018.110174

[50] Oğuzoğlu T, Ertürk A, Çizmeci Ş, Koç B, Akça Y. A Report on Bovine Ephemeral Fever Virus in Turkey: Antigenic Variations of Different Strains of EFV in the 1985 and 2012 Outbreaks Using Partial Glycoprotein Gene Sequences.. Transboundary and Emerging Diseases. 2015. DOI: https://doi.org/10.1111/tbed.12187

[51] Niwa T, Shirafuji H, Ikemiyagi K, Nitta Y, Suzuki M, Kato T, et al.. Occurrence of bovine ephemeral fever in Okinawa Prefecture, Japan, in 2012 and development of a reverse-transcription polymerase chain reaction assay to detect bovine ephemeral fever virus gene. Journal of Veterinary Medical Science. 2014. DOI: https://doi.org/10.1292/jvms.14-0492

[52] Hsu H, Yeh S, Chen C, Ke G. CHO Cell-Produced Truncated Bovine Ephemeral Fever Virus Glycoprotein as a Promising Subunit Vaccine Candidate for Cattle. Vaccines. 2026. DOI: https://doi.org/10.3390/vaccines14030265

[53] Zeng Y, Hsu M, Tsai C, Chu C, Wu H, Wang H. A Senescence-Like Cellular Response Inhibits Bovine Ephemeral Fever Virus Proliferation. bioRxiv. 2021. DOI: https://doi.org/10.3390/vaccines9060601

[54] Zheng W, Zhao Z, Tian L, Liu L, Xu T, Wang X, et al.. Genetically Modified Rabies Virus Vector-Based Bovine Ephemeral Fever Virus Vaccine Induces Protective Immune Responses against BEFV and RABV in Mice.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13796

[55] Hansoongnern P, Kaewborisuth C, Wasanasuk K, Chankeeree P, Poonsuk S, Lekcharoensuk C, et al.. The immunogenicity of the secretory GΔTM protein of bovine ephemeral fever virus stably expressed by mammalian cells.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/J.VETMIC.2019.04.032

[56] Zhang M, Ge J, Wen Z, Chen W, Wang X, Liu R, et al.. Characterization of a recombinant Newcastle disease virus expressing the glycoprotein of bovine ephemeral fever virus. Archives of Virology. 2016. DOI: https://doi.org/10.1007/s00705-016-3078-2

[57] Salem Z, El-Shemindy OA, Aly N. Influence of using of saponin-carbopol mixture adjuvant on the potency of freeze-dried Bovine Ephemeral Fever virus vaccine. المجلة العربیة للعلوم الزراعیة. 2019. DOI: https://doi.org/10.21608/asajs.2019.52887

[58] Kanpipit N, Kaewborisuth C, Rungnirundorn T, Petcharat N, Lekcharoensuk P. Immunogenicity of transmembrane deleted-G protein of bovine ephemeral fever virus (BEFV) expressed in insect cells. TURKISH JOURNAL OF VETERINARY AND ANIMAL SCIENCES. 2018. DOI: https://doi.org/10.3906/vet-1711-7

[59] Pyasi S, Jonniya NA, Sk M, Nayak D, Kar P. Finding potential inhibitors against RNA-dependent RNA polymerase (RdRp) of bovine ephemeral fever virus (BEFV): an in-silico study. Journal of Biomolecular Structure and Dynamics. 2021. DOI: https://doi.org/10.1080/07391102.2021.1946714